Becton Dickinson settles charges over infusion pump risks, SEC says

WASHINGTON (Reuters) – The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson (NYSE:BDX) and Co. over allegations it misled investors about risks associated with its Alaris infusion pump.

The SEC said Becton Dickinson agreed to pay a $175 million civil penalty to settle the charges, which also allege that the company overstated its income by failing to disclose the costs of software repairs associated with the pump.